Research Services

MRI Data Analytics and Consulting Services

The success of your drug candidates rely on your speed to market and compelling data for adoption. Clinical trials require significant time, costs, and energy, but with the right partner, you can maximize the success of your clinical trials and derisk drug R&D.

With AMRA, you not only get access to our MRI data analysts, global research sites, and high-precision body composition analysis, you also get a team of subject matter experts that know exactly what you need to generate robust data and propel your R&D projects to the next stage—as smoothly and as quickly as possible.

MRI Data Analytics and Consulting Services

Clinical Protocol Design

Get guidance on which of our biomarkers to use and how to implement them—from study startup to commercialization.

Exploratory Biomarkers

Develop a new way of looking at your data using our existing and upcoming MRI-based measurements.

Expert Data Analytics

Support mission-critical R&D decision-making by understanding what your MRI data truly means.

Maximize the success of drug R&D with end-to-end clinical research services

Optimize Your Clinical Protocol Design

Save time and resources by involving AMRA early to help design your clinical protocol to ensure regulatory clearance. AMRA offers pharmaceutical companies expert input on clinical trials for wide-ranging therapeutic areas to help you answer key questions surrounding clinical study design, such as:

Which AMRA body composition measurements to use and which muscles to evaluate
When to use virtual control groups and how to implement them
Where in the body a drug may cause changes in muscle and fat volumes
How to establish inclusion criteria using AMRA’s MRI-based measurements
Communications with regulatory agencies on trial design and key biomarkers

Whether you are launching a single-site pilot study or multisite Phase III clinical trial, we can help you optimize your clinical protocol.

Explore New Applications for Body Composition Biomarkers

Use our body composition biomarkers in new ways to deepen your insights into complex pathological disease processes. Our biomarkers are driven by our constantly growing body composition database and machine learning approach.

We continue to develop new biomarkers and are also developing composite scores for neuromuscular disorders. Contact us to see what biomarkers are currently available and being developed for your next study!

Get Expert MR Imaging Analysis and Interpretation

What does the MRI data mean and what does it contribute? These are common questions researchers need to answer to make the data meaningful and understandable to key stakeholders, R&D management, regulatory agencies, early adopters, and potential investors.

Fortunately, AMRA can quickly interpret body composition measurements for you.

Our Clinical Research Areas Include

Is Your Research Area Not Listed? We can still support you! Contact Us to learn more.

Musculoskeletal

Neuromuscular

Diabetes

Obesity

Cardiovascular

Liver

Sarcopenia

Cachexia

Metabolic Research

Move your trials forward quickly and confidently with whole-body MRI and body composition measurements—because accurate data fuels breakthrough therapeutics.

Musculoskeletal Research

Get never before possible whole-body muscle and muscle fat measurements —uncompromised quality and precision is changing what’s possible in NMD.

Derisk Drug R&D From The Start

Set up a high-impact clinical study, consider adding additional imaging biomarkers, and easily understand your MR imaging data. From study start up through regulatory clearances, AMRA is dedicated to supporting you to:

Confidently make high-stakes go/no-go decisions to help determine if you should move forward with a drug candidate
Substantially save time and resources by potentially identifying drugs destined to fail or succeed
Build confidence in your therapeutic by generating robust and compelling data
Transform exploratory imaging biomarkers into secondary or primary endpoints in a clinical trial

An Optimized Clinical Protocol for Whole-Body MRI in FSHD

AMRA and Fulcrum developed an optimized whole-body magnetic resonance imaging (MRI) protocol and analysis that correlates with clinical outcome assessments in Facioscapulohumeral Muscular Dystrophy (FSHD). The use of MRI and AMRA’s automated measurements can detect small and large changes in muscle—potentially before changes in FSHD-relevant clinical endpoints, providing information earlier on disease severity and progression.